Beijing Strong Biotechnologies,Inc. (SHE:300406)
13.26
+0.10 (0.76%)
Feb 4, 2026, 3:04 PM CST
SHE:300406 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,422 | 1,648 | 1,737 | 1,508 | 1,598 | 847.24 |
Other Revenue | 11.28 | 11.28 | 4.4 | 2.88 | 1 | 0.88 |
| 1,433 | 1,659 | 1,742 | 1,511 | 1,599 | 848.12 | |
Revenue Growth (YoY) | -17.88% | -4.75% | 15.27% | -5.53% | 88.58% | 0.86% |
Cost of Revenue | 291.05 | 361.88 | 445.01 | 384.12 | 448.5 | 328.44 |
Gross Profit | 1,142 | 1,297 | 1,297 | 1,127 | 1,151 | 519.67 |
Selling, General & Admin | 428.95 | 457.67 | 491.04 | 457.36 | 444.38 | 244.92 |
Research & Development | 186.81 | 188.53 | 162.9 | 137.2 | 127.01 | 79.06 |
Other Operating Expenses | 24.95 | 15.45 | 14.97 | 12.85 | 12.92 | 2.88 |
Operating Expenses | 649.11 | 665.03 | 692.35 | 625.46 | 602.71 | 353.83 |
Operating Income | 493.09 | 632.01 | 604.27 | 501.29 | 548.17 | 165.84 |
Interest Expense | -48.36 | -47.61 | -46.99 | -52.64 | -21.59 | -8.16 |
Interest & Investment Income | 19.57 | 19.82 | 25.95 | 21.48 | 15.74 | 6.61 |
Currency Exchange Gain (Loss) | -0.1 | -0.1 | -0.12 | 2.21 | -0.29 | 0.84 |
Other Non Operating Income (Expenses) | 3.9 | 2.39 | -3.5 | -28.33 | -19.94 | -25.09 |
EBT Excluding Unusual Items | 468.1 | 606.52 | 579.62 | 444.01 | 522.09 | 140.04 |
Impairment of Goodwill | - | - | - | -3.03 | - | - |
Gain (Loss) on Sale of Investments | -1.04 | - | - | - | - | 0.06 |
Gain (Loss) on Sale of Assets | -1.81 | -2.11 | -3.5 | -2.68 | 0.16 | -1.03 |
Asset Writedown | -1.38 | -1.38 | -0.21 | -2.29 | -0.11 | -0.18 |
Other Unusual Items | 22.25 | 17.66 | 17.64 | 13.35 | 14.85 | -1.96 |
Pretax Income | 486.12 | 620.69 | 593.55 | 449.35 | 536.99 | 136.93 |
Income Tax Expense | 54.29 | 89.53 | 71.48 | 54.89 | 67.33 | 15.25 |
Earnings From Continuing Operations | 431.83 | 531.16 | 522.07 | 394.46 | 469.66 | 121.68 |
Minority Interest in Earnings | -0.12 | 1.47 | 1.67 | -5.37 | -64.01 | -9.4 |
Net Income | 431.71 | 532.64 | 523.74 | 389.1 | 405.65 | 112.28 |
Net Income to Common | 431.71 | 532.64 | 523.74 | 389.1 | 405.65 | 112.28 |
Net Income Growth | -17.90% | 1.70% | 34.60% | -4.08% | 261.30% | -66.15% |
Shares Outstanding (Basic) | 579 | 579 | 582 | 581 | 588 | 548 |
Shares Outstanding (Diluted) | 592 | 592 | 595 | 614 | 588 | 548 |
Shares Change (YoY) | -1.02% | -0.56% | -3.00% | 4.37% | 7.25% | 9.09% |
EPS (Basic) | 0.75 | 0.92 | 0.90 | 0.67 | 0.69 | 0.20 |
EPS (Diluted) | 0.73 | 0.90 | 0.88 | 0.67 | 0.69 | 0.20 |
EPS Growth | -17.05% | 2.27% | 31.47% | -2.99% | 236.88% | -68.97% |
Free Cash Flow | 598.81 | 546.36 | 437.06 | 299.69 | 275.9 | 105.81 |
Free Cash Flow Per Share | 1.01 | 0.92 | 0.73 | 0.49 | 0.47 | 0.19 |
Dividend Per Share | 0.900 | 0.400 | 0.200 | 0.100 | 0.100 | 0.099 |
Dividend Growth | 350.00% | 100.00% | 100.00% | - | 0.66% | -33.77% |
Gross Margin | 79.69% | 78.19% | 74.45% | 74.58% | 71.96% | 61.27% |
Operating Margin | 34.40% | 38.10% | 34.70% | 33.18% | 34.27% | 19.55% |
Profit Margin | 30.12% | 32.11% | 30.07% | 25.75% | 25.36% | 13.24% |
Free Cash Flow Margin | 41.78% | 32.93% | 25.09% | 19.84% | 17.25% | 12.48% |
EBITDA | 572.94 | 700.68 | 658.03 | 554.35 | 590.51 | 196.05 |
EBITDA Margin | 39.98% | 42.24% | 37.78% | 36.69% | 36.92% | 23.12% |
D&A For EBITDA | 79.85 | 68.67 | 53.76 | 53.05 | 42.33 | 30.21 |
EBIT | 493.09 | 632.01 | 604.27 | 501.29 | 548.17 | 165.84 |
EBIT Margin | 34.40% | 38.10% | 34.70% | 33.18% | 34.27% | 19.55% |
Effective Tax Rate | 11.17% | 14.42% | 12.04% | 12.22% | 12.54% | 11.14% |
Revenue as Reported | 1,433 | 1,659 | 1,742 | - | 1,599 | - |
Advertising Expenses | - | 153.01 | 194.01 | 200.07 | 186.98 | 106.68 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.